| 摘要 |
The invention relates to 5 identified protein biomarkers, gamma- and beta-Actin proteins, for screening, diagnosis, drug targeting, and drug design for resistance of cancer to an Ab1 kinase inhibitor. The method is based on the use of two-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in bone marrow aspirate samples, taken from patients at time of diagnosis of Chronic Myelogenous Leukemia (CML), the quantitation of 5 protein spots identified as beta- and/or gamma-Actin proteins, to differentiate between patients who will respond to or resist treatment when the patients are subsequently treated with an Ab1 kinase inhibitor.
|
